Name
        Heavy chain desposition disease
    
ICD-O-2 Morphology
9762/3: Heavy chain disease
    9763/3: Gamma heavy chain disease
    
                    Effective
                    1992 - 2000
                
            
        ICD-O-3 Morphology
        
    9762/3: Heavy chain disease
    
                    Effective
                    2001 and later
                
            
        Reportable
        for cases diagnosed 
    1992 and later
    
Primary Site(s)
        See Module 7
    
See abstractor notes for the most common sites of involvement for the different variants.
        
                    Coding Manual:
                    
                        Hematopoietic Coding Manual (PDF)
                    
                
            
            
                Abstractor Notes
Heavy chain diseases are rare. There are several different variants.
Note that heavy chain deposition disease is not the same as HCD; the deposition term is non-reportable and would be coded 9769/1, if collected.
1. Gamma heavy chain disease (Gamma HCD) - a variant of lymphoplasmacytic lymphoma (9671/3) but is a distinct and separate disease. It may involve the lymph nodes, Waldeyer ring, gastrointestinal tract, and other extranodal sites, plus the bone marrow, liver, spleen, and peripheral blood. Most patients have systemic symptoms and generalized disease, including lymphadenopathy and hepatosplenomegaly. Prognosis is extremely variable. Low-grade disease may respond to chemotherapy.
2. Mu heavy chain disease - resembles CLL (9823/3) because of its small, round lymphocytes but it is a distinctly different entity. This is the rarest HCD. It involves spleen, liver, bone marrow, and peripheral blood. Peripheral lymphadenopathy is usually not present. Hepatosplenomegaly is frequent. The disease usually progresses slowly.
3. Alpha heavy chain disease - the most common HCD, is a variant of extranodal marginal zone lymphoma of MALT (9699/3) but it is classified with the other HCD’s. It mainly occurs in young adults and involves the gastrointestinal tract, mainly the small intestine and mesenteric lymph nodes. Gastric and colonic mucosa may be involved. The bone marrow and other organs are usually not involved. Rare respiratory tract involvement is described. Antibiotic therapy (coded as chemotherapy) is very effective on Alpha heavy chain disease. A newer term for alpha HCD is immunoproliferative small intestinal disease (IPSID); these terms had separate codes before 2010.
4. Immunoproliferative small intestinal disease - this variant was recently added to the growing list of infectious pathogen-associated human lymphomas. IPSID involves mainly the proximal small intestine. Geographically, IPSID is most prevalent in the Middle East and Africa.
    Note that heavy chain deposition disease is not the same as HCD; the deposition term is non-reportable and would be coded 9769/1, if collected.
1. Gamma heavy chain disease (Gamma HCD) - a variant of lymphoplasmacytic lymphoma (9671/3) but is a distinct and separate disease. It may involve the lymph nodes, Waldeyer ring, gastrointestinal tract, and other extranodal sites, plus the bone marrow, liver, spleen, and peripheral blood. Most patients have systemic symptoms and generalized disease, including lymphadenopathy and hepatosplenomegaly. Prognosis is extremely variable. Low-grade disease may respond to chemotherapy.
2. Mu heavy chain disease - resembles CLL (9823/3) because of its small, round lymphocytes but it is a distinctly different entity. This is the rarest HCD. It involves spleen, liver, bone marrow, and peripheral blood. Peripheral lymphadenopathy is usually not present. Hepatosplenomegaly is frequent. The disease usually progresses slowly.
3. Alpha heavy chain disease - the most common HCD, is a variant of extranodal marginal zone lymphoma of MALT (9699/3) but it is classified with the other HCD’s. It mainly occurs in young adults and involves the gastrointestinal tract, mainly the small intestine and mesenteric lymph nodes. Gastric and colonic mucosa may be involved. The bone marrow and other organs are usually not involved. Rare respiratory tract involvement is described. Antibiotic therapy (coded as chemotherapy) is very effective on Alpha heavy chain disease. A newer term for alpha HCD is immunoproliferative small intestinal disease (IPSID); these terms had separate codes before 2010.
4. Immunoproliferative small intestinal disease - this variant was recently added to the growing list of infectious pathogen-associated human lymphomas. IPSID involves mainly the proximal small intestine. Geographically, IPSID is most prevalent in the Middle East and Africa.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
    Grade
        
     
        
            Not Applicable
        
    
    
Module Rule
        None
    
Alternate Names
Alpha heavy chain disease (AHCD)
    Franklin disease
    Gamma heavy chain disease (GHCD)
    Heavy chain disease (NOS) (HCD)
    Immunoproliferative small intestinal disease (IPSID)
    
    Mu heavy chain disease (MHCD)
    Definition
The heavy chain diseases (HCD) are three rare B-cell neoplasms characterized by the production of monoclonal immunoglobulin heavy chains (IgG in gamma HCD, IgA in alpha HCD, and IgM in mu HCD) and typically no light chains.
    Definitive Diagnostic Methods
Bone marrow biopsy
    Genetic testing
    Histologic confirmation
    Immunophenotyping
    Genetics Data
Deletions in Alpha, Gamma, or Mu heavy chain gene
    Incomplete immunoglobulin molecule
    
    Immunophenotyping
CD5 and CD10- (no expression/negative) (AHCD)
    CD20+ CD5-, CD10- on marginal zone cells (AHCD)
    CD20-, DC138+ on plasma cells (AHCD)
    CD79a and CD20 on lymphocytic component (AHCD)
    Express B-cell antigens (AHCD)
    Monoclonal cytoplasmic alpha chain without light chain on plasma cells and marginal zone cells (GHCD)
    Monoclonal cytoplasmic gamma chain without light chains  (GHCD)
    Monoclonal cytoplasmic Mu heavy chain, with or without monotypic light chain  (MHCD)
    Treatments
Chemotherapy
    Other therapy
    Transformations to
Transformations from
        None
    
Same Primaries
Corresponding ICD-9 Codes
203.8 Other immunoproliferative neoplasms
    Corresponding ICD-10 Codes
C88.1 Alpha heavy chain disease
    C88.2 Gamma heavy chain disease
    Corresponding ICD-10-CM Codes (U.S. only)
C88.2 Heavy chain disease (effective October 01, 2015)
    Signs and Symptoms
Abdominal pain (alpha)
    Anorexia (gamma)
    Diarrhea (alpha)
    Fever (alpha & gamma)
    Hemolytic anemia (gamma)
    Hepatosplenomegaly (mu)
    Hypocalcemia (alpha)
    Malabsorption (alpha)
    
    Rheumatoid arthritis (gamma)
    Thrombocytopenia (gamma)
    Vasculitis (gamma)
    Wasting (alpha)
    Weakness (gamma)
    Weight loss (gamma)
    Diagnostic Exams
Blood chemistry studies
    Bone marrow aspiration and biopsy
    CT (CAT) scan
    
    Cytogenetic analysis
    Immunophenotyping
    Peripheral blood smear
    
    Progression and Transformation
        None
    
Epidemiology and Mortality
Age: 20-30 years peak incidence, involves young age group (alpha)
    Age: 60 years median age (gamma and mu)
    Country: Israel, Egypt, Saudi Arabia, North Africa (alpha)
    Country: Immunoproliferative small intestinal disease (IPSID) occurs in the Middle East, Cape region of South Africa and other tropical and subtropical locations
    Incidence: most common of the heavy chain diseases (alpha)
    Incidence: very rare (gamma and mu)
    Sex: slight male predominance (gamma)
    Sex: no male or female predominance (alpha and mu)
    Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 237-240
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 237-240
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
    Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
                
 Home